

CATO RESEARCH LTD AND DUSKA THERAPEUTICS PLAN MEETING WITH THE FDA ON ATPace

Durham, NC, and La Jolla, CA, March 11, 2008 — **Duska Therapeutics, Inc.** (OTC BB:DSKA.OB - News), a biotechnology company developing medical products based on adenosine 5'-triphosphate (ATP) and P2 receptor-related technologies, announced today that its senior management and consultants are scheduled to meet with representatives of the U.S. Food and Drug Administration's (FDA) Division of Cardiovascular and Renal Products in April to discuss the regulatory pathway for obtaining marketing approval of ATPace(tm), an intravenous formulation of ATP.

Duska requested a Type C advisory meeting with the FDA to present, discuss and obtain answers to several questions submitted by the company related to the regulatory pathway of ATPace(tm). The company intends to file an NDA under Section 505(b)(2) of the FDA for ATPace(tm) as an antiarrhythmic drug for the conversion of paroxysmal supraventricular tachycardia (PSVT) to normal sinus rhythm. The company believes that the meeting with the FDA will yield a pathway for eventual marketing approval of the drug.

Currently, Duska has an Investigational New Drug application with the FDA on ATPace(tm) and has collected clinical data on ATPace(tm) in diagnosing bradycardic neurally-mediated syncope.

“Together with our CRO, **CATO Research**, we are looking forward to having a productive meeting with the FDA that we expect will enable us to bring ATPace to the U.S. market in an expeditious manner” said Dr. James Kuo, Duska's Chairman and Chief Executive Officer. “Duska's founders played a critical role in introducing the first adenosine product to the market, and we seek to put the first ATP pharmaceutical product on the U.S. market,” he added.

About ATPace and PSVT

ATPace is a proposed, intravenous drug for the acute treatment and diagnosis of certain cardiac arrhythmias (abnormal heart rate). These include terminating PSVT, a rapid regular heart rate originating in the atria, and diagnosing bradycardia (slow heart rate), which is one of the main causes of syncope (fainting). PSVT is one of the most common cardiac arrhythmias and is currently treated in the U.S. with adenosine, a by-product of ATP. Intravenous ATP has been used in Europe as a diagnostic and therapeutic drug for more than five decades.

About Cato Research

Founded in 1988 by Allen Cato, M.D., Ph.D., and Lynda Sutton and headquartered near Research Triangle Park, Cato Research is a global, full-service contract research and development organization providing strategic and tactical support for clients in the pharmaceutical, biotechnology, medical device, and medical diagnostic industries. With a staff of more than 300 employees located in the United States, Europe, Canada, Israel,

and South Africa, Cato Research's services range from design and management of preclinical and clinical studies to submission of regulatory documents required for marketing approval. For more information, visit Cato's website at <http://www.cato.com>.

About Duska

Duska Therapeutics, Inc., based in La Jolla, California, is an emerging biotechnology company that is focused on the development of therapeutic, medical device and diagnostic products related to adenosine 5'-triphosphate (ATP) and cell-surface P2 receptors (P2R). Duska owns or has exclusive license rights to a number of proprietary products, four of which are currently in various stages of development for the treatment and diagnosis of certain cardiac arrhythmias, enhancement of sperm motility, treatment of chronic obstructive pulmonary disorder, and mitigation of the toxic effects of radiation exposure. For more information, visit Duska's website at <http://www.duskatherapeutics.com>.